Levosta

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levosta

Property Description
Active ingredient Levofloxacin (INN)
Form Tablet, Solution for infusion, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic
Common use Systemic bacterial infections
Origin Synthetic compound (Quinolone derivative)

Levosta is a brand name for a prescription-only medicine whose active component is Levofloxacin, a potent substance recognized internationally as a synthetic broad-spectrum antibacterial agent. The drug is commonly used to counter systemic bacterial infections, representing a core therapeutic option in adult medicine.

What Type of Medicine is Levosta (Levofloxacin)?

Levosta belongs to the Fluoroquinolone antibiotic pharmacological class, functioning as a powerful single active ingredient product. Levofloxacin is chemically unique among its class as it is the purified S-(-) enantiomer (or S-isomer) of the older, racemic drug Ofloxacin. This distinction is significant: this chiral switch concentrates the therapeutic activity, resulting in higher antibacterial potency compared to the R-(+) isomer. Levofloxacin is noted for its enhanced activity against important respiratory pathogens, a differentiating factor from earlier quinolones.

Levofloxacin: Composition, Origin, and Available Forms

The core active ingredient, Levofloxacin, is entirely synthetic in origin, designed around a fundamental Quinolone derivative structure. To meet varying clinical needs, Levofloxacin is available in multiple pharmaceutical preparations. These forms include standard tablets for oral use, an aqueous solution for infusion for hospital-based intravenous (IV) administration, and specialized ophthalmic solutions (drops) intended for localized topical treatment. The availability of these distinct presentations ensures the medicine can be applied across different sites of infection.

What is the General Therapeutic Purpose of Levofloxacin?

The general purpose of Levofloxacin is the elimination of pathogenic bacteria by initiating cell death. It achieves this goal by interfering with bacterial DNA synthesis, specifically targeting Topoisomerase II (DNA gyrase) and Topoisomerase IV. This targeted, cell-killing mechanism of effect is why the drug is clinically utilized for its efficacy in addressing serious systemic bacterial infections.

Regulatory References

  1. NIH, Levofloxacin Profile

What side effects are possible with Levosta?

Official Safety Profile and Adverse Reactions

The safety profile of Levofloxacin (Levosta) is formally structured by government regulatory agencies, classifying potential adverse reactions by both frequency and the physiological system affected. The most common effects documented include insomnia, headache, dizziness, nausea, and diarrhea.

Less common documented reactions include vomiting, abdominal pain, rash, itching, and joint or muscle pain (arthralgia or myalgia). These effects are organized across various System-Organ Classes (SOC), such as Gastrointestinal Disorders, Nervous System Disorders, and Musculoskeletal and Connective Tissue Disorders.


Serious Adverse Reactions

Regulatory documentation emphasizes the potential for severe, disabling, and potentially irreversible reactions, which are classified as serious. These include Tendonitis and Tendon Rupture, which can occur during or months after treatment, and Peripheral Neuropathy (nerve damage) that may develop rapidly after initiation. The official label also notes the risk of Aortic Aneurysm and Dissection, particularly in older adults, and potential blood glucose disturbances (hypo- or hyperglycemia), especially in diabetic patients. Other serious documented risks include QT interval prolongation and severe skin reactions.


Time-Related Patterns and Restrictions

Safety notes specify that certain reactions are not limited to the treatment period. For instance, tendon disorders can manifest up to several months following the last dose. The official safety data restricts use in individuals with a history of tendon disorders related to previous quinolone use or conditions that predispose to seizures.

Overdose and Emergency Response

In the event of an acute Levofloxacin overdose, immediate medical attention is required to manage potentially serious manifestations. The official regulatory profile describes overdosage primarily associated with Central Nervous System (CNS) effects and severe gastrointestinal reactions. Documented CNS effects may include increased confusion, dizziness, tremor, and the possibility of convulsive seizures. Gastrointestinal symptoms such as nausea and mucosal erosions have also been reported. The risk of these CNS effects is noted to be elevated in older patients and in individuals with renal impairment.

Due to the drug's properties, overdosage carries the risk of serious complications, notably QT interval prolongation, which necessitates specialized continuous ECG monitoring in a hospital setting. The official prescribing information mandates specific actions: the stomach should be emptied, and the patient must be observed while appropriate hydration is maintained. Treatment is strictly symptomatic and supportive as no specific antidote is known for Levofloxacin overdose.

A crucial constraint noted in regulatory documents is that the drug is not efficiently removed by hemodialysis or peritoneal dialysis. Immediate consultation with a physician in an emergency department is necessary when an overdose is suspected, especially if symptoms like seizures or signs of severe cardiac disturbance occur.

Therapeutic Uses of Levosta

What Levosta treats: Main Uses and Benefits

Levofloxacin (Levosta) is a broad-spectrum antibacterial agent used in situations involving symptoms driven by bacterial pathogens across several body systems. Its primary therapeutic purpose is to support the elimination of causative bacteria to assist with symptomatic relief and general patient comfort.


Key Therapeutic Contexts

This medication is commonly used to help with bacterial infections, including Community-Acquired Pneumonia, acute bacterial exacerbations of chronic bronchitis, complicated urinary tract infections, and infections such as acute pyelonephritis (kidney infection) and Chronic Bacterial Prostatitis. It helps address symptom clusters related to inflammatory states and organ-specific functional stress, such as high fever, discomfort when breathing, and painful urination. The benefit is providing supportive symptomatic assistance that may help ease the overall burden of acute illness and reduces temporary functional strain.

In specialized clinical settings, Levofloxacin is also applied for addressing acute or disruptive symptom patterns, including its use for post-exposure prophylaxis against specific pathogens like Inhalational Anthrax.


Quick Fact: Relief for Respiratory Stress Quick Fact: Use for Complicated Infections
Helps address persistent cough and fever associated with pneumonia. Applied when infections are complex, such as kidney or prostate involvement.

Eligibility and Restrictions for Use

Levosta (Levofloxacin) has strict eligibility requirements defining who can and cannot use the medicine, as detailed in official regulatory documents.

Contraindications (Must Not Use)

Levosta is contraindicated and must not be used in several populations:

  • Patients with known hypersensitivity to levofloxacin or any other quinolone antibiotic.
  • Patients with epilepsy or a history of tendon disorders related to prior fluoroquinolone use.
  • Children and growing adolescents (general use) and patients with a known history of myasthenia gravis (use must be avoided).
  • During pregnancy and in breast-feeding women.

Age and Physiological Restrictions

  • Adults (mathbfge 18 years) are the primary approved population.
  • Pediatric use is not established for infants younger than mathbf6 months of age and is restricted to specific, severe infections (like Inhalational Anthrax/Plague) for children mathbfge 6 months of age.
  • Patients with renal impairment (reduced kidney function) require dosage adjustment based on the degree of impairment.
  • Caution is necessary for older adults (mathbfge 60 years) and those taking corticosteroids due to an increased risk of tendon rupture. Use should be avoided in these specific, high-risk cases.
  • For certain common infections (e.g., Uncomplicated Urinary Tract Infection, Acute Bacterial Sinusitis), Levosta is reserved for use only when no alternative treatment options are available.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Levosta (Levofloxacin) details several clinically significant interactions that impose specific usage constraints.

Pharmacokinetic Interactions (Drug Exposure Changes)

Interacting Product Category Mechanistic Basis Regulatory Restriction
Multivalent Cations (e.g., Antacids, Sucralfate, Iron/Zinc Supplements, Didanosine) Chelation reduces oral absorption of Levosta. Oral Levosta must be separated from these products by at least two hours before or after administration.
Probenecid, Cimetidine Inhibition of renal tubular secretion increases Levosta systemic exposure. Use with caution and clinical monitoring is required.

Pharmacodynamic Interactions (Additive Risk)

Interacting Product Category Interacting Medicines (Examples) Regulatory Constraint/Monitoring
QT Prolonging Agents Class IA and III Antiarrhythmics (e.g., Quinidine, Amiodarone, Sotalol). Co-administration is generally discouraged due to additive risk of QT interval prolongation.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ibuprofen, Naproxen. Use with caution; may increase the risk of Central Nervous System (CNS) stimulation and convulsions.
Antidiabetic Agents Insulin, Oral Hypoglycemic Agents (e.g., Glyburide). Requires careful and frequent monitoring of blood glucose levels due to reported fluctuations.
Warfarin Anticoagulant. Requires close monitoring of Prothrombin Time/INR due to potential enhancement of the anticoagulant effect.

Official labeling mandates the avoidance or time-separation of certain combinations, while others necessitate increased clinical oversight, such as glucose and coagulation status checks, to mitigate documented risks.

Mechanism of Action

The following text describes the pharmacodynamic mechanism of Levofloxacin (Levosta), detailing the molecular targets and subsequent cellular cascade, without referencing indications, dosing, or safety.

Mechanism of Action

Levofloxacin functions as a targeted enzyme inhibitor, acting primarily on two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug interrupts the fundamental processes required for bacterial genetic maintenance and replication by stabilizing the transient DNA-enzyme cleavage complex. This interaction prevents the enzyme from resealing the DNA strand after breakage.

The inhibition of these topoisomerases leads directly to the accumulation of lethal double-strand DNA breaks throughout the bacterial genome. This massive, irreversible damage overwhelms the microbial cell's intrinsic repair mechanisms, initiating a definitive, cell-killing (bactericidal) process. This molecular cascade is the core physiological action that results in the destruction of susceptible microbial cells.

The functional reach of this mechanism is constrained by bacterial adaptations, specifically target-site mutations that reduce the drug's binding affinity to the enzymes, and active efflux pump systems that physically expel the drug from the cell, thus limiting the bactericidal effect against resistant strains.

Dosage and Administration Information

The instructions for using levofloxacin define a specific administration protocol for its oral and intravenous dosage forms. Adherence to the prescribed once-daily dosing regimen and the full treatment duration is necessary, with regimens spanning from 3 to 60 days depending on the type of use.

Administration Protocol

Attribute Administration Guidance
Route(s) of Administration Oral (Tablet, Oral Solution) or Intravenous (IV) Infusion
Frequency and Dosing Typically Once Daily (q24h) at doses of 250 mg, 500 mg, or 750 mg.
Timing Relative to Meals Tablets can be taken with or without food. Oral Solution should be taken one hour before or two hours after eating.
Drug Interaction Constraint Oral formulations must not be taken within two hours of multivalent cation-containing products, such as antacids, metal cations, or didanosine, to prevent decreased absorption.

Special Administration Conditions

  • IV Infusion: The intravenous form must be administered as a slow infusion over either 60 or 90 minutes, depending on the prescribed dose. Rapid intravenous or bolus administration is prohibited. Single-use vials require dilution to 5 mg/mL prior to infusion.
  • Renal Adjustment: Dosage and/or the interval between doses must be adjusted for adult patients when the calculated creatinine clearance is less than 50 mL/min.
  • Pediatric Use: Specific weight-based dosing (e.g., 8 mg/kg twice daily) is specified for pediatric patients (age 6 months and older) for certain documented uses, such as post-exposure prophylaxis for anthrax.

Recent Clinical Evidence

Research evidence / Overview of studies for Levosta

Levosta, which contains the active ingredient Levofloxacin, was studied for various acute and chronic bacterial infections. The available evidence is largely drawn from Randomized Controlled Trials (RCTs) that research examined using a variety of protocols, including different dosing schedules and comparison regimens. These studies typically monitored high-level clinical response (such as stabilization of symptoms) and the measured microbiological eradication rate.


Evidence for Use in Acute and Complicated Urinary Tract Infections

The research for complicated urinary tract infections (cUTI) and acute pyelonephritis (a kidney infection) primarily involves short-term RCTs that research examined in adult populations. The main outcomes that researchers studied for this indication included the patient's clinical response (describing changes in symptoms like fever or painful urination) and the microbiological eradication rate (measuring the clearance of pathogenic bacteria from the urine).

However, the existing evidence also highlights areas of uncertainty. Evidence is limited for long-term outcomes, such as recurrence rates months after treatment completion. Furthermore, the data for certain groups remain insufficient, particularly for patients with specific complicating factors like indwelling catheters.


Evidence for Use in Respiratory and Systemic Infections

Levofloxacin was studied for conditions associated with acute or disruptive episodes, such as Community-Acquired Pneumonia (CAP) and acute exacerbations of chronic bronchitis. For CAP, the research examined patients with varying degrees of illness severity, measuring both clinical response status and the clearance of respiratory pathogens. Studies monitored outcomes such as the measurement of time until fever stabilization and rates of hospitalization. For conditions like chronic bronchitis exacerbations, research highlights that regulatory assessments now focus on its evaluation for patients who lack alternative treatments that were evaluated in the research.


Research Gaps and Remaining Uncertainties

A major uncertainty is the increasing prevalence of bacterial resistance, which may impact the future measured outcomes reported in initial clinical trials. Additionally, long-term function and symptom return well after the medication is completed is not fully established, as follow-up durations were limited in many acute studies.

Frequently Asked Questions (FAQ)

Common questions about Levosta (FAQ)


Q: Can I take Levosta if I have a history of [common organ] issues?

A: Official regulatory information focuses on the need for dosage adjustment in individuals with existing kidney (renal) impairment.

While rare cases of liver (hepatic) injury have been documented in the safety profile, specific contraindications for chronic liver issues are generally not listed in the same manner as for kidney function or certain nervous system disorders.


Q: Is it normal to feel [mild side effect] when first starting Levosta?

A: The official safety profile describes common effects such as nausea, headache, and diarrhea.

While time frames are not given for every minor effect, these generally tend to manifest closer to the start of treatment. It is important to know that serious adverse reactions, such as tendon rupture, have been documented to occur during therapy or even several months after the medicine is stopped.


Q: Are there any common foods or drinks that interact with Levosta?

A: The tablet form can be taken with or without food. However, official regulatory documents state that oral Levosta must not be taken within two hours of products containing multivalent cations, such as certain antacids or iron/zinc mineral supplements.

Most common fruit juices are generally not listed as a specific interaction in the regulatory documentation.


Q: What happens if I stop taking Levosta suddenly?

A: Official regulatory guidelines emphasize the importance of adhering to the prescribed duration.

Discontinuing the medication prematurely should only occur under the guidance of a healthcare professional.


Q: What should I do if I miss a dose of Levosta? (non-directive)

A: If an administration is missed, official instructions suggest taking it as soon as it is remembered.

If it is nearly time for the next scheduled administration, the missed dose should be skipped entirely. Official instructions specify that patients must not take two doses at the same time, as this carries a risk of potential overexposure.


Q: Does Levosta stay in your system for a long time after you stop using it?

A: Pharmacokinetic data indicates that the medicine's half-life—the time it takes for half of the drug to be eliminated from the body—is about 6 to 8 hours.

While this means the substance is typically cleared from the body within a few days, it is important to note that certain serious documented effects, such as tendon disorders, can still manifest months later.


Q: Why is Levosta sometimes given alongside [other common drug class]?

A: Official clinical guidelines state that for certain severe infections, such as specific cases of hospital-acquired pneumonia or tuberculosis, Levosta is documented for use in combination with other anti-infective agents.

In these cases, it is used alongside other anti-infective agents to address a broad range of potential pathogens.


Q: Does Levosta have a generic version available?

A: The active ingredient in Levosta is Levofloxacin.

Following patent expiration, generic versions of Levofloxacin are now widely available internationally.


Q: Can Levosta interact with herbal supplements like St. John's Wort?

A: Regulatory documentation indicates that interactions between Levosta and herbal products have not been formally established or fully studied.

Official guidance emphasizes that disclosure of all supplements to a healthcare professional is important for comprehensive risk management.


Q: Has Levosta been studied in diverse patient populations?

A: While clinical trial protocols aim for broad representation, regulatory documents do not specifically detail the inclusion of diverse ethnic or racial groups in the research data.

The official efficacy and safety data are generally considered applicable to the overall approved adult population.


Q: What does the term 'Levosta-related photosensitivity' mean?

A: Official safety documents list photosensitivity as a potential adverse effect.

This means the medicine can cause the skin to become excessively sensitive to ultraviolet (UV) light, including sunlight and sunlamps. This reaction is considered a form of phototoxicity.


Q: What is the difference between Levosta and a placebo in clinical trials?

A: In the context of clinical trials, Levosta is the active medicine being investigated for its effects.

A placebo is a non-active substance that is designed to look identical to the active medicine. The placebo serves as a neutral baseline to accurately measure the true effects and efficacy of Levosta against an inactive comparator.


Q: Is there a specific time of day recommended for taking Levosta?

A: The typical regimen is prescribed as a once-daily administration.

While there is no mandatory time of day specified in regulatory documents, it is generally advised that for optimal consistency, the medicine should be taken at approximately the same time every day. Note that the oral solution has specific timing guidelines related to food.


Q: Does Levosta affect the effectiveness of birth control pills?

A: Official information indicates that, like some other antibiotics, Levosta may reduce the effectiveness of hormonal contraceptives, such as birth control pills.

Official information suggests consulting a healthcare professional regarding the potential need for alternative or additional contraceptive measures during the treatment period.


Q: Are there different brand names for the medicine Levosta?

A: Yes, Levofloxacin is the active ingredient, and it is marketed under several different brand names internationally.

A well-known example is Levaquin.


Q: Can Levosta be crushed or split if swallowing is difficult?

A: Official administration guidelines, particularly those related to use in children, confirm that Levofloxacin tablets can be crushed.

They may then be mixed with a small amount of soft food, like applesauce or pudding, to assist administration when swallowing is difficult.


Q: Does the package insert for Levosta include information about mental health side effects?

A: Yes, the official package insert explicitly includes warnings about potential Central Nervous System (CNS) effects.

These effects may include psychiatric symptoms such as anxiety, depression, hallucinations, and suicidal thoughts or acts, which are listed as potential adverse reactions.


Q: Is Levosta prescribed for things other than its main approved uses?

A: Official regulatory documentation details a specific list of approved uses, known as indications.

The labeling also states that for certain common infections, the medicine is reserved for use only when no other treatment options are deemed appropriate.


Q: How reliable is the evidence base for Levosta according to official sources?

A: The evidence base for Levosta is founded on rigorous Randomized Controlled Trials (RCTs) that examined clinical efficacy.

However, the official documentation also points to areas of uncertainty, specifically noting limitations in long-term follow-up data and the challenge posed by increasing bacterial resistance.


Q: Are there restrictions on driving or operating machinery while taking Levosta?

A: Official warnings note that Levosta has the potential to cause side effects affecting the Central Nervous System, such as dizziness, lightheadedness, or confusion.

Regulatory documents note that effects such as dizziness or confusion may impair the ability to operate machinery. Caution is therefore advised in the product information regarding driving or operating equipment.


Q: Why is patient information about Levosta labeled with a 'Black Box Warning'?

A: The Black Box Warning is the strongest safety advisory that a regulatory body can require for patient information.

It is mandated for Levosta to draw attention to the risk of serious, disabling, and potentially irreversible adverse reactions. These include, but are not limited to, tendon rupture, nerve damage (peripheral neuropathy), and certain effects on the central nervous system.


Q: What happens if I accidentally take two doses of Levosta close together? (non-directive)

A: In the event that more than the prescribed amount is accidentally taken, the official patient information indicates that immediate consultation with a healthcare professional or pharmacist is advised.


Q: Do certain genetic factors affect how Levosta works?

A: Regulatory documents do not currently mandate genetic testing before using Levosta.

However, research indicates that individual genetic variability can influence the body's processing (pharmacokinetics) and the ultimate effect (pharmacodynamics) of antibiotics, which may affect both the therapeutic outcome and the risk of experiencing adverse effects.

How should Levosta be stored and disposed of?

How to Store and Dispose of Levosta (Levofloxacin)

Official regulatory guidelines dictate specific conditions for storing and discarding Levosta to maintain its efficacy and ensure safety.


Storage Requirements

Levofloxacin tablets and injection solutions must be stored at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F). The injection solution must also be protected from light. Any constituted oral suspension requires refrigeration (2°C to 8°C) and must not be frozen. It is mandatory to keep the medicine in its original container and out of the sight and reach of children.

Disposal Instructions

Unused or expired Levosta should be returned to a drug take-back program. The medicine should not be flushed down the toilet or poured down a sink. If a take-back program is unavailable, official guidance recommends mixing the medication with an unappealing substance (like dirt or coffee grounds) and sealing it in a bag before placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levosta found in:

A-Z Index: